XINSORB西罗莫司洗脱生物可吸收血管支架5年连续血管内成像结果 - Suppr | 超能文献

相似文献

1

5 Years of Serial Intravascular Imaging Outcomes of XINSORB Sirolimus-Eluting Bioresorbable Vascular Scaffold.XINSORB西罗莫司洗脱生物可吸收血管支架5年连续血管内成像结果

JACC Cardiovasc Interv. 2019 Mar 25;12(6):602-603. doi: 10.1016/j.jcin.2018.11.029. Epub 2019 Jan 16.

2

Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery.XINSORB生物可吸收西罗莫司洗脱支架治疗人类冠状动脉单发性初发病变的6个月结果

Catheter Cardiovasc Interv. 2016 Mar;87 Suppl 1:630-7. doi: 10.1002/ccd.26404. Epub 2016 Feb 10.

3

Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.随机比较 Absorb 生物可吸收血管支架和 Mirage 微纤维西罗莫司洗脱支架的多模式影像学研究。

JACC Cardiovasc Interv. 2017 Jun 12;10(11):1115-1130. doi: 10.1016/j.jcin.2017.03.015. Epub 2017 May 17.

4

6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study.新型放射显影西罗莫司洗脱生物可吸收血管支架 6 个月的临床和血管造影结果：FANTOM II 研究。

JACC Cardiovasc Interv. 2017 Sep 25;10(18):1832-1838. doi: 10.1016/j.jcin.2017.07.033.

5

First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).首例人体生物可吸收聚合物涂层依维莫司洗脱支架的评估：DESOLVE I 试验（载有依维莫司和生物可吸收聚合物的 DES 治疗原发性冠状动脉病变患者）的影像学和临床结果。

JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.

6

Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.新型 DESolve 雷帕霉素洗脱生物可吸收冠状动脉支架系统治疗单支原发冠状动脉病变的 2 年临床结局及系列多模态影像学研究

JACC Cardiovasc Interv. 2016 Mar 28;9(6):565-74. doi: 10.1016/j.jcin.2015.12.004.

7

Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.新型西罗莫司洗脱生物可吸收支架治疗初发冠状动脉疾病的安全性和有效性：NeoVas 试验前瞻性患者水平汇总分析的 1 年结果。

Catheter Cardiovasc Interv. 2019 Feb 15;93(S1):832-838. doi: 10.1002/ccd.28067.

8

One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the NeoVas bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions.单发性初发冠状动脉病变患者植入NeoVas生物可吸收西罗莫司洗脱支架后的一年临床结局及多层螺旋计算机断层扫描血管造影结果

Catheter Cardiovasc Interv. 2018 Feb 15;91(S1):617-622. doi: 10.1002/ccd.27491. Epub 2018 Feb 2.

9

Second-generation drug-eluting stents and bioresorbable vascular scaffolds in patients with diabetes.糖尿病患者使用第二代药物洗脱支架和生物可吸收血管支架的情况

JACC Cardiovasc Interv. 2014 May;7(5):494-6. doi: 10.1016/j.jcin.2014.01.156.

10

Serial assessment of bioresorbable-polymer sirolimus-eluting stent by coronary angioscopy and optical coherence tomography.通过冠状动脉血管内镜和光学相干断层扫描对生物可吸收聚合物西罗莫司洗脱支架进行连续评估。

Coron Artery Dis. 2017 Sep;28(6):530-531. doi: 10.1097/MCA.0000000000000499.

引用本文的文献

1

Identification of endothelial protein C receptor as a novel druggable agonistic target for reendothelialization promotion and thrombosis prevention of eluting stent.鉴定内皮细胞蛋白C受体为促进洗脱支架再内皮化和预防血栓形成的新型可成药激动靶点。

Bioact Mater. 2024 Aug 9;41:485-498. doi: 10.1016/j.bioactmat.2024.07.028. eCollection 2024 Nov.

2

Hot spots and trends in PCI prognostic research: A bibliometric analysis with CiteSpace.经皮冠状动脉介入治疗（PCI）预后研究的热点和趋势：基于 CiteSpace 的文献计量分析。

Medicine (Baltimore). 2023 Oct 27;102(43):e35599. doi: 10.1097/MD.0000000000035599.

3

The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial.